Elicio Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$4,889	$5,039	$18,457	$19,823
General and administrative	3,563	3,006	11,026	9,049
Total operating expenses	8,452	8,045	29,483	28,872
Loss from operations	(8,452)	(8,045)	(29,483)	(28,872)
Other income (expense)
Change in fair value of warrant liabilities	708	(1,811)	2,207	(3,177)
Foreign exchange transaction (loss) gain	(4)	—	10	—
Grant income	—	—	—	415
Interest income	237	199	532	577
Interest expense	(413)	(426)	(1,230)	(796)
Total other income (expense), net	528	(2,038)	1,519	(2,981)
Loss before taxes	(7,924)	(10,083)	(27,964)	(31,853)
Income tax expense	(55)	—	(55)	—
Net loss	(7,979)	(10,083)	(28,019)	(31,853)
Other comprehensive income:
Foreign currency translation adjustment	(1)	39	—	144
Comprehensive loss	$(7,980)	$(10,044)	$(28,019)	$(31,709)
Net loss per common share, basic and diluted	$(0.30)	$(0.60)	$(1.32)	$(2.09)
Weighted average common shares and pre-funded warrants outstanding, basic and diluted	26,291,534	16,692,476	21,278,916	15,247,864

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.